Monoclonal Antibody Therapeutics Market, By Source (Human, Chimeric, Murine, and Humanized), by Application (Cancer, Autoimmune Disease, Hematological Disease, Infectious Disease, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Apr 2023

Code : CMI2403

Pages :335

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Challenges And Opportunities

Global Monoclonal Antibody Therapeutics Market – Driver

Increasing prevalence of infectious diseases  

Increasing prevalence of infectious diseases needs the use of monoclonal antibody therapeutics for treatment which, is expected to drive the monoclonal antibody therapeutics market over the forecast period. For instance, on 25 January 2023, according to a report published by Centers for Disease Control and Prevention (CDC), stated that the number of emergency department visits with infectious diseases as the primary diagnosis was 3.2 million respectively.

Global Monoclonal Antibody Therapeutics Market: Restraint

Side effects of using monoclonal antibody therapeutics

The global monoclonal antibody therapeutics market can be hindered by side effects associated with the use of monoclonal antibody therapeutics. For instance, in November 2022, according to an article published by American Cancer Society, Inc., a nationwide voluntary health organization dedicated to eliminating cancer, stated Bevacizumab (Avastin), an monoclonal antibody that targets a protein called vascular endothelial growth factor (VEGF) that affects tumor blood vessel growth. It can cause side effects such as high blood pressure, bleeding, poor wound healing, blood clots, and kidney damage.

Therefore, improved monoclonal antibody therapeutics with lesser side effects may help in increasing the wider application of monoclonal antibody therapeutics and can tackle these restraints.

Market Restraints